Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Ophthalmol.

Sec. Lens and Cataract

Volume 5 - 2025 | doi: 10.3389/fopht.2025.1618276

This article is part of the Research TopicMechanisms and Prevention Strategies for Posterior Capsule Opacification Post-Cataract SurgeryView all articles

MyoD is required for the differentiation of Myo/Nog cell progenitors of myofibroblasts in explants of human lens tissue

Provisionally accepted
Jackie  GerhartJackie Gerhart1Mara  CrispinMara Crispin1Brian  HeistsBrian Heists1Keith  MathersKeith Mathers2Joseph  InfantiJoseph Infanti1David  VenutiDavid Venuti1Joseph  RichardsJoseph Richards1Steven  MorencySteven Morency1Cathy  J HatcherCathy J Hatcher1Mindy  George-WeinsteinMindy George-Weinstein1*
  • 1Philadelphia College of Osteopathic Medicine (PCOM), Philadelphia, United States
  • 2Bala Eye Care, Bala Cynwyd, PA, United States

The final, formatted version of the article will be published soon.

Posterior capsule opacification (PCO) is a complication of cataract surgery that impairs vision. Clouding and distortion of the posterior capsule occur as a result of cell migration, deposition of exrtracellular matrix proteins and contractions of myofibroblasts. The subpopulation of Myo/Nog cells differentiate into myofibroblasts in the lens. Myo/Nog cells express MyoD, Noggin and brain-specific angiogenesis inhibitor (BAI1). Depletion of Myo/Nog cells in the rabbit lens during cataract surgery prevented the emergence of myofibroblasts and reduced PCO to below clinically significant levels. A requirement for MyoD in the differentiation of Myo/Nog cells to myofibroblasts was explored in explant cultures of human anterior lens tissue. Tissue was incubated with MyoD or non-targeting siRNA. MyoD and Noggin mRNAs were co-expressed in control cultures. The number of MyoD mRNA-positive (+) cells was reduced by 90% after treatment with MyoD siRNA. The Noggin mRNA+ population was significantly increased with MyoD knockdown. Nearly all cells with BAI1 contained MyoD protein and all had Noggin. The MyoD family members Myf5 and Myogenin were also synthesized in Myo/Nog cells. Most cells with BAI1 contained alpha smooth muscle actin (α-SMA) and striated muscle myosin (SMM). MyoD siRNA nearly eliminated Myogenin and SMM, and significantly reduced the number of BAI1+ cells with Myf5. Expression of α-SMA was unaffected by MyoD knockdown. The numbers of BAI1+ cells was increased in response to treatment with MyoD siRNA. Noggin and muscle proteins were not detected in LECs in control explants or after MyoD knockdown. Cell free areas of the capsule were surrounded by differentiated Myo/Nog cells in control cultures. Wrinkles in the capsule were visible within these areas. Wrinkles were reduced by approximately 75% after MyoD knockdown. These results indicate that MyoD lies upstream of Myogenin, Myf5 and SMM in Myo/Nog cells of the lens. Contractions that deform the anterior capsule are dependent on SMM but not α-SMA. This study demonstrates that MyoD drives Myo/Nog cell differentiation to contractile myofibroblasts in cultures of human anterior lens tissue. The resulting increase in the progenitor population indicates that temporary knockdown of MyoD is not a therapeutic option for preventing of PCO.

Keywords: Posterior capsule opacification, lens, Myofibroblasts, MyoD, Myo/Nog cells

Received: 25 Apr 2025; Accepted: 18 Jun 2025.

Copyright: © 2025 Gerhart, Crispin, Heists, Mathers, Infanti, Venuti, Richards, Morency, Hatcher and George-Weinstein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mindy George-Weinstein, Philadelphia College of Osteopathic Medicine (PCOM), Philadelphia, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.